CellCyte Genetics Corp. (OTC: CCYG) is the developer and holder of several innovative technologies with the potential to fundamentally alter the face of stem cell therapy and make tissue and organ regenerative medicine a reality. In addition to its stem cell purification platform and its proprietary three-dimensional bioreactor cell expansion and incubation technology (the first of its kind), CellCyte Genetics has a robust therapeutic division which holds the technology that may solve one of the most significant barriers to successful implementation of stem cell therapy: effective cell delivery and organ retention of the stem cells. CellCyte is completing IND enabling pre-clinical trials of its first proprietary products that are designed to non-invasively and non-traumatically deliver stem cells to diseased or dying areas of the body. This step is critical to any stem cell therapeutic process or therapy, and CellCyte is moving forward with the development of this essential new innovation.